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What are they? Tumour suppressors
implicated in hereditary
predisposition to breast cancer.
Women who inherit a mutation in
one copy of BRCA1 or BRCA2 are at
high risk of developing breast and
some other cancers. These typically
appear at a younger age than the
average for non-hereditary
(sporadic) breast cancer. And,
mutations in BRCA2 can give men
breast cancer too.
But isn't inherited breast cancer quite
rare? Well of course most breast
cancers aren’t hereditary. Inherited
predisposition accounts for about 5%
of all breast cancers — mutations in
BRCA1 and BRCA2 probably cause
a significant proportion of these.
So BRCA mutation doesn’t cause a
high fraction of all breast cancers,
but, because this disease is so
common (about 1 in 10 lifetime risk),
it adds up to quite a few cases.
Mutations are also found more
frequently in certain populations,
e.g. Ashkenazi Jews.
Will studying these genes tell us
anything about sporadic breast cancer?
That’s the hope. Although BRCA
genes are not mutated in sporadic
breast cancers, BRCA1 protein levels
have been shown to be reduced in
the majority of non-hereditary high
grade breast cancers. It is also
possible that other components of
the pathway(s) in which the BRCA
proteins act are disrupted in
sporadic disease.
So where do these proteins hang out?
For some time with BRCA1 this
depended on who you asked —
nuclear, cytoplasmic, centrosomal,
and even cytoplasmic invaginations
into the nucleus have all been
touted. However, the consensus
localisation is now nuclear. BRCA2
has been less controversial and only
reported in the nucleus. So far.
And what do they do? Despite having
no significant sequence similarity,
BRCA1 and BRCA2 are implicated
in similar cellular processes. For
BRCA1, a simpler question might
be, “what doesn’t it do?”. So far it
has been implicated in DNA repair,
transcriptional regulation,
centrosome duplication, and a cell
cycle checkpoint. BRCA2 is less of a
renaissance molecule, but it’s
catching up fast. However, virtually
nothing is known about how they
might contribute to the biochemistry
of any of these processes, despite a
plethora of proteins to which they
allegedly bind.
Don’t we get any clues to their
biochemistry from their sequence? With
proteins this long (1,863 and 3,418
amino acids for BRCA1 and BRCA2,
respectively) you’d hope so. BRCA1
has a RING-finger at one end and two
BRCT (BRCA1-terminal) domains at
the other. Several RING-finger
proteins facilitate ubiquitination, so
BRCA1 may regulate the cellular
processes it’s involved in by targeting
other proteins, or itself, for
degradation. BRCT domains are
found in a variety of proteins involved
in DNA repair, recombination and cell
cycle checkpoints, but their
biochemical function is unknown.
The BRCA2 sequence is less helpful,
having no domains in common with
other proteins. But it does contain
eight so-called BRC repeats —
binding sites for RAD51, which plays
a key role in DNA repair.
Is there some clarity developing?
Maybe. A consensus is developing
that, by virtue of their DNA repair
function, the BRCA proteins play a
role in the maintenance of genomic
stability. In this scenario, loss of
BRCA function would precipitate
genetic instability, leading to
tumourigenesis. However, this does
not exclude a role for loss of other
functions of the proteins contributing
to cancer progression.
Who owns them? Who indeed.
There’s been a big hoo-haa about
this. If you’ll pardon the cliché, it’s a
“paradigm” for the gene patenting
issue. Two schools of thought on this:
Either:
“Yes, it’s perfectly reasonable that
genes are owned by private
companies who can have a monopoly
position on testing.”
Or:
“Get your filthy hands off our
genes.”
While most scientists are in the
second camp, there’s still a
“myriad” (Inc.) of interested parties
in the first.
What’s on the horizon, then? There’s
good evidence for a BRCAX (3,4,5…)
gene and this or these should make
an appearance sooner or later. In
terms of therapeutics, straightforward
gene replacement therapy is
probably a non-starter; given the role
of BRCA proteins in genomic
stability this would be like closing
the stable door after the horse has
bolted. Therapeutic hopes rest on
attempting to exploit biochemical
alterations, perhaps in DNA repair,
in BRCA-associated tumours.
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